Drug intelligence / Profile preview

VVD-4009

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

**VVD-4009** is a small molecule inhibitor selectively targeting the **AKT1-E17K** mutant, a hyperactive oncogenic variant of AKT1 (protein kinase B) frequently found in certain cancers. Developed for oncology applications, it demonstrates potent antitumor activity, achieving complete and durable tumor regression in preclinical models of **AKT1-E17K-driven triple-negative breast cancer (TNBC)** patient-derived xenografts (PDX) upon oral administration at 120 mg/kg twice daily (BID). Its mutant-specific mechanism aims to block aberrant PI3K/AKT signaling while sparing wild-type AKT to minimize toxicity.[1]

Targets

AKT1 E17K (AKT serine/threonine kinase 1 E17K mutant)

Beyond the preview

Go deeper on VVD-4009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VVD-4009.

Explore the full profile